These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18645192)

  • 1. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
    Cady FM; O'Neill BP; Law ME; Decker PA; Kurtz DM; Giannini C; Porter AB; Kurtin PJ; Johnston PB; Dogan A; Remstein ED
    J Clin Oncol; 2008 Oct; 26(29):4814-9. PubMed ID: 18645192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
    Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
    Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interphase detection of BCL6/IgH fusion gene in non-Hodgkin lymphoma by fluorescence in situ hybridization.
    Ueda Y; Nishida K; Miki T; Horiike S; Kaneko H; Yokota S; Misawa S; Abe T; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 1997 Dec; 99(2):102-7. PubMed ID: 9398863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene.
    Kanda-Akano Y; Nomura K; Fujita Y; Horiike S; Nishida K; Nagai M; Miura I; Nakamura S; Seto M; Iida S; Ueda R; Taniwaki M
    Leuk Lymphoma; 2004 Aug; 45(8):1559-67. PubMed ID: 15370207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
    J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
    Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
    Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner.
    Montesinos-Rongen M; Akasaka T; Zühlke-Jenisch R; Schaller C; Van Roost D; Wiestler OD; Siebert R; Deckert M
    Brain Pathol; 2003 Oct; 13(4):534-8. PubMed ID: 14655758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.
    Akasaka T; Lossos IS; Levy R
    Blood; 2003 Aug; 102(4):1443-8. PubMed ID: 12738680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
    Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
    Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.